{"nctId":"NCT01054573","briefTitle":"VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo","startDateStruct":{"date":"2010-04"},"conditions":["Hepatitis C, Chronic"],"count":90,"armGroups":[{"label":"Telaprevir + Standard Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Telaprevir","Drug: pegylated interferon (Peg-IFN) alfa-2a","Drug: ribavirin (RBV)"]}],"interventions":[{"name":"Telaprevir","otherNames":[]},{"name":"pegylated interferon (Peg-IFN) alfa-2a","otherNames":[]},{"name":"ribavirin (RBV)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient from the control group of the C216 study who failed therapy for virologic reasons\n* Patient must have completed all assessments in the C216 trial\n* Patient must be willing to use 2 effective methods of birth control for up to 7 months after last dose of study medication\n\nExclusion Criteria:\n\n* Patient received any direct acting anti-viral HCV therapy after discontinuation of the C216 trial\n* Patient has history of decompensated liver disease\n* Patient has history of acute or chronic pancreatitis\n* Patient has condition that requires use of systemic corticosteroids\n* Patient who prematurely stopped medication for non-compliance or for whom it would be unsafe to repeat treatment\n* Patient has history of decompensated liver disease or history of cirrhosis with hepatocellular carcinoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual)","description":"The table below shows the percentage of participants acheiving a SVR 24 weeks after the last dose of study drug defined as having plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \\< 25 IU/mL, target not detected at end of treatment (EOT) AND the participant did not relapse AND the participant completed the treatment; OR if the participant had plasma HCV RNA levels of \\< 25 IU/mL, target not detected at EOT AND the participant did not relapse AND the participant prematurely discontinued at least one study medication, but never for the reason virologic failure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":null},{"groupId":"OG001","value":"72.7","spread":null},{"groupId":"OG002","value":"81.5","spread":null},{"groupId":"OG003","value":"44.4","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected at Different Time Points","description":"The table below shows the percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels of less than 25 IU/ml, target not detected at different time points during the study. Data was imputed for participants with missing values using the last observation carried forward (LOCF) method for missing values.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"77.3","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null},{"groupId":"OG001","value":"86.4","spread":null},{"groupId":"OG002","value":"92.6","spread":null},{"groupId":"OG003","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"90.9","spread":null},{"groupId":"OG002","value":"92.6","spread":null},{"groupId":"OG003","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"77.3","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"81.8","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"72.7","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"86.4","spread":null},{"groupId":"OG002","value":"92.6","spread":null},{"groupId":"OG003","value":"77.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue Telaprevir and Continue Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) at Week 4 or Week 8","description":"The table below shows the percentage of participants at Week 4 or 8 who met a stopping rule defined as having a hepatitis C virus (HCV) ribonucleic acid (RNA) value \\>100 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"3.7","spread":null},{"groupId":"OG003","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue All Study Drugs at Week 12, 24, or 36","description":"The table below shows the percentage of participants at Week 12, 24, and 36 who met a stopping rule. The stopping rule at Week 12 was having hepatitis C virus (HCV) ribonucleic acid (RNA) value of \\>100 IU/mL and the stopping rule at Weeks 24 or 36 was having a HCV RNA value of \\>=25 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"9.1","spread":null},{"groupId":"OG002","value":"3.7","spread":null},{"groupId":"OG003","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Rapid Virologic Response (RVR)","description":"The table below shows the percentage of participants who had a rapid virologic response (RVR) (ie, those with undetectable hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA values of \\<25 IU/mL, target not detected at Week 4 of treatment).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"77.3","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR)","description":"The table below shows the percentage of participants who had a Extended Rapid Virologic Response (eRVR) (ie, those with undetectable hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA values of \\<25 IU/mL, target not detected at at Weeks 4 and 12 of treatment).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":null},{"groupId":"OG001","value":"72.7","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Breakthrough","description":"The table below shows the percentage of participants with viral breakthrough defined as a confirmed increase \\>1 log10 in hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached during the considered treatment phase up to the considered time point, if the lowest level reached is \\> 25 IU/mL, or a confirmed value of HCV RNA \\>100 IU/mL in participants whose HCV RNA had previously become \\<25 IU/mL (detected or target not detected) during the considered treatment phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"9.1","spread":null},{"groupId":"OG002","value":"3.7","spread":null},{"groupId":"OG003","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Relapsed During Follow-Up","description":"The table below shows the percentage of participants who relapsed (ie, those having confirmed detectable hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA\\] during the 24-week follow-up period after previous HCV RNA \\<25 IU/mL, target not detected, at end of treatment).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"4.0","spread":null},{"groupId":"OG003","value":"28.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values Over Time","description":"The table below shows plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) values measured over time.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.63","spread":null},{"groupId":"OG001","value":"6.72","spread":null},{"groupId":"OG002","value":"6.48","spread":null},{"groupId":"OG003","value":"6.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":null},{"groupId":"OG001","value":"0.70","spread":null},{"groupId":"OG002","value":"0.70","spread":null},{"groupId":"OG003","value":"1.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null},{"groupId":"OG001","value":"0.70","spread":null},{"groupId":"OG002","value":"0.70","spread":null},{"groupId":"OG003","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null},{"groupId":"OG001","value":"0.70","spread":null},{"groupId":"OG002","value":"0.70","spread":null},{"groupId":"OG003","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null},{"groupId":"OG001","value":"0.70","spread":null},{"groupId":"OG002","value":"0.70","spread":null},{"groupId":"OG003","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null},{"groupId":"OG001","value":"0.70","spread":null},{"groupId":"OG002","value":"0.70","spread":null},{"groupId":"OG003","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null},{"groupId":"OG001","value":"0.70","spread":null},{"groupId":"OG002","value":"0.70","spread":null},{"groupId":"OG003","value":"0.70","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level","description":"The table below shows change from baseline in log 10 plasma HCV RNA values measured over time.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.39","spread":null},{"groupId":"OG001","value":"-5.83","spread":null},{"groupId":"OG002","value":"-5.59","spread":null},{"groupId":"OG003","value":"-5.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.51","spread":null},{"groupId":"OG001","value":"-5.88","spread":null},{"groupId":"OG002","value":"-5.62","spread":null},{"groupId":"OG003","value":"-5.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.40","spread":null},{"groupId":"OG001","value":"-5.88","spread":null},{"groupId":"OG002","value":"-5.62","spread":null},{"groupId":"OG003","value":"-5.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.89","spread":null},{"groupId":"OG001","value":"-5.72","spread":null},{"groupId":"OG002","value":"-5.75","spread":null},{"groupId":"OG003","value":"-5.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.95","spread":null},{"groupId":"OG001","value":"-5.86","spread":null},{"groupId":"OG002","value":"-5.78","spread":null},{"groupId":"OG003","value":"-6.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.03","spread":null},{"groupId":"OG001","value":"-5.88","spread":null},{"groupId":"OG002","value":"-5.71","spread":null},{"groupId":"OG003","value":"-6.07","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Fatigue","Pruritus","Anaemia","Nausea","Headache"]}}}